Ilgyun Im

Aug 23, 2023 | insights.bio | Rebecca Lim |Ilgyun Im

The clinical manufacturing of gene-modified cell-based immunotherapies is complex and labor-intensive. Despite its widespread application, the use of viral vectors for transgene delivery comes with limitations, including high costs, biosafety challenges, and regulatory restrictions. Key current areas of focus for industry include the optimization of non-viral gene delivery methods, and closing and automating cell processing to improve overall safety and cost-effectiveness.